Alimera Sciences, Inc.
(NASDAQ : ALIM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.95%176.301.2%$600.82m
GILDGilead Sciences, Inc.
0.62%68.020.9%$542.46m
BIIBBiogen Inc.
-0.06%280.401.2%$519.30m
CELGCelgene Corporation
-2.01%78.371.2%$513.71m
REGNRegeneron Pharmaceuticals, Inc.
-2.01%301.812.6%$316.79m
ALXNAlexion Pharmaceuticals, Inc.
-0.07%121.072.0%$253.26m
ILMNIllumina, Inc.
0.45%269.673.5%$244.32m
VRTXVertex Pharmaceuticals Incorporated
0.58%157.241.9%$236.54m
NKTRNektar Therapeutics
7.66%85.306.0%$212.18m
AAgilent Technologies, Inc.
1.15%64.321.5%$199.05m
INCYIncyte Corporation
1.79%67.832.5%$194.51m
SRPTSarepta Therapeutics, Inc.
1.78%93.4816.6%$131.29m
EXASExact Sciences Corporation
2.43%52.3625.5%$116.06m
BMRNBioMarin Pharmaceutical Inc.
0.51%88.884.4%$114.43m
ALNYAlnylam Pharmaceuticals, Inc
1.15%102.819.8%$103.66m

Company Profile

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its portfolio includes ILUVIEN and NADPH Oxidase Inhibitors. The company was founded on June 4, 2003 by Daniel C. Myers and David R. Holland and is headquartered in Alpharetta, GA.